New England Biolabs® (NEB®) has announced the launch of its Luna®SARS-CoV-2 RT-qPCR Multiplex Assay Kit for real-time detection of SARS-CoV-2 nucleic acid. This research use only (RUO) kit offers multiplex testing of up to 94 samples in a single 96-well plate, with the additional capacity for supporting sample pooling and high throughput applications using 384-well plate test formats....
New England Biolabs® (NEB®) has announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA. The kit serves as a simple alternative to RT-qPCR and enables visual detection of amplification of SARS-CoV-2 nucleic acid in just 30 minutes.
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, has announced it has signed an agreement with New England Biolabs (NEB®), a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes for molecular biology applications, to commercialise a product using the Affimer technology for use in both life science research and diagnostics assays. Avacta and NEB have been collaborating to develop Affimers to combine with NEB’s reagents....
New offering will include integrated and comprehensive product development services for fast tracking innovation, progressing ideas into commercial products
TTP plc, a leading technology and product development company, and New England Biolabs, Inc. (NEB®), an industry leader in the discovery and production of enzymes for molecular biology applications, announce that they have established a non-exclusive partnership...
Several innovations yield unmatched reproducibility and consistency of NGSlibraries
New England Biolabs® (NEB®) announces the release of the NEBNext Library Quant Kit for Illumina®, a qPCR-based solution for accurate next generation sequencing library quantitation. This kit offers several improvements over other commercially available library quantitation methods, including greater accuracy and, consequently, higher correlation with cluster numbers, higher reproducibility, a more convenient protocol and supplied kit components...
Population Genetics Assigns Asymmetric Adaptor Library Construction Patent To New England Biolabs
Population Genetics Technologies Ltd (PGT) and New England Biolabs, Inc. (NEB) announce that PGT has assigned exclusive rights to a patent (US 8,420,319) covering methods for asymmetric adaptor library construction to NEB. As part of next generation sequencing (NGS) library preparation, this technology enables increased efficiency at the adaptor ligation step, resulting in high yield libraries and minimized adaptor-dimer formation. In conjunction with NEB’s other innovations in NGS library preparation, this patent further strengthens the NEBNext® product portfolio...
The latest issue ofIntegrated DNA Technologies' (IDT's) DECODED newsletter highlights how New England Biolabs (NEB) researchers were able to expedite the cloning of a 2.1 kb gene into a linearized pET21-a bacterial expression vector using 5 gBlocksTM Gene Fragments that spanned the entire 2.1 kb sequence. Cloning, sequencing, and characterization of protein activity took less than 4 days, shorter than necessary for a third party to synthesize the complete gene and provide a finished construct.
New England Biolabs® (NEB®) has announced the launch of its Luna®SARS-CoV-2 RT-qPCR Multiplex Assay Kit for real-time detection of SARS-CoV-2 nucleic acid. This research use only (RUO) kit offers multiplex testing of up to 94 samples in a single 96-well plate, with the additional capacity for supporting sample pooling and high throughput applications using 384-well plate test formats....
New England Biolabs® (NEB®) has announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA. The kit serves as a simple alternative to RT-qPCR and enables visual detection of amplification of SARS-CoV-2 nucleic acid in just 30 minutes. 
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, has announced it has signed an agreement with New England Biolabs (NEB®), a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.
TTP plc, a leading technology and product development company, and New England Biolabs, Inc. (NEB®), an industry leader in the discovery and production of enzymes for molecular biology applications, announce that they have established a non-exclusive partnership...
New England Biolabs® (NEB®) announces the release of the NEBNext Library Quant Kit for Illumina®, a qPCR-based solution for accurate next generation sequencing library quantitation. This kit offers several improvements over other commercially available library quantitation methods, including greater accuracy and, consequently, higher correlation with cluster numbers, higher reproducibility, a more convenient protocol and supplied kit components...
The latest issue of Integrated DNA Technologies' (IDT's) DECODED newsletter highlights how New England Biolabs (NEB) researchers were able to expedite the cloning of a 2.1 kb gene into a linearized pET21-a bacterial expression vector using 5 gBlocksTM Gene Fragments that spanned the entire 2.1 kb sequence. Cloning, sequencing, and characterization of protein activity took less than 4 days, shorter than necessary for a third party to synthesize the complete gene and provide a finished construct.